Opendata, web and dolomites

SACCSCAN

SACCSCAN - personalising clinical management of major psychiatric disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SACCSCAN project word cloud

Explore the words cloud of the SACCSCAN project. It provides you a very rough idea of what is the project "SACCSCAN" about.

version    near    validation    5t    internet    time    medicine       abnormalities    share    diagnostic    market    quality    reducing    plan    precision    commercialise    excess    detect    95    lifetime    speed    economy    clinical    health    poc    33    demonstrated    proof    showed    job    50    complete    treatment    mental    customer    care    2030    receive    significantly    performed    billion    receiving    breakdown    saccscan    personalising    exposing    extended    suspected    tool    phase    costing    initial    manual    depression    deterioration    diagnose    savings    us    biomarkers    disorder    utilises    6t    minimum    symptoms    impede    accuracy    worldwide    software    life    million    illness    family    disability    diagnosis    bipolar    projected    business    serious    self    patient    segments    introducing    movement    schizophrenia    point    criteria    harming    eye    instrument    annum       recognised    risk    services    global    economic    adopter    healthcare    474    successfully    meet    ill    illnesses    sme    total    minutes    10    delays    don    patients    purpose   

Project "SACCSCAN" data sheet

The following table provides information about the project.

Coordinator
SACCADE DIAGNOSTICS LIMITED 

Organization address
address: 2 LISTER SQUARE
city: EDINBURGH
postcode: EH3 9GL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.saccade-diagnostics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SACCADE DIAGNOSTICS LIMITED UK (EDINBURGH) coordinator 50˙000.00

Map

 Project objective

1 in 5 of us experience mental health problems during our lifetime but more than 50% of patients don’t receive adequate care. Currently, when patients’ symptoms and behaviour don’t meet the criteria set out in the diagnostic manual, it may take up to 10 years to diagnose the illness. Delays in receiving a diagnosis can significantly impede delivery of the most effective treatment plan, exposing the patient to risk of further deterioration in well-being, reduction in quality of life leading to job loss, family breakdown, and self-harming. Mental ill health is now recognised as the largest cause of short and long term disability worldwide costing the global economy US$2.5T with a projected increase to over US$6T by 2030. SaccScan is a novel point-of-care (PoC) software diagnostic system which has been demonstrated to detect schizophrenia with better than 95% accuracy and has been extended with the same precision to bipolar disorder and major depression illnesses. The software diagnostic tool successfully utilises eye-movement abnormalities as clinical diagnostic biomarkers for serious mental illnesses. The test can be performed within 30 minutes and results produced over the internet at near real-time speed. Early economic modelling showed that introducing SaccScan into health care services could produce savings of €33 474 per patient in the case of suspected schizophrenia. The global market for this test is in excess of €5 billion with early-adopter customer segments making up over 10% of the total market - creating a potential initial market share of €100 million per annum. The purpose of this Phase 1 application is to demonstrate proof of business and develop the necessary partnerships for bringing a minimum viable version to market. Further support from H2020 SME Instrument, will help complete clinical validation and fully commercialise SaccScan in Phase 2 and Phase 3, while addressing the EU challenge of reducing healthcare costs through personalising medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SACCSCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SACCSCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More